Annie Cunningham is a Field Application Scientist at Terumo Blood and Cell Technologies, where she serves as a technical expert and product trainer for Quantum Flex® and FINIA® Fill and Finish platforms. She has spent her career engaged in the biotechnology industry, beginning at Seattle Genetics where she was part of the BLA submission and FDA approval of ADCETRIS®, an antibody drug conjugate for CD30+ blood cancer. She then shifted focus into immunotherapy and contributed to the development of the CAR-T program at Juno Therapeutics, now Bristol Myers Squibb. She holds a BS in Human Biology from Michigan State University.